Lacamas Laboratories

What Lacamas Laboratories does

Lacamas Laboratories is a privately-held, founder-led custom manufacturer of pharmaceutical intermediates and fine chemicals headquartered in Portland, Oregon. Founded in 1985 by Allen Erickson (Ph.D. in organic chemistry, Purdue 1981), the company operates two Oregon facilities — Portland (headquarters and primary manufacturing) and Albany (secondary manufacturing) — with over 32,000 gallons of reactor capacity spanning 5-gallon to 2,000-gallon vessels. Core technical capabilities include custom organic synthesis, cryogenic reactions to -80°C, high-temperature reactions to 300°C, corrosive chemistry (thionyl chloride, phosphorus oxychloride), organometallic chemistry (diisopropylzinc, Grignard reagents on ton scale), continuous processing for hazardous materials, triphosgene handling for chloroformates/carbamates, phosgene-free isocyanate preparation, ultra-high-vacuum distillation, thin-film evaporation, and a 25-plate distillation unit capable of 12,000 kg/day. Quality systems are anchored by ISO 9001:2015 certification, cGMP compliance, and an independent Quality Unit (QA and QC) reporting directly to management.

The business operates a B2B custom manufacturing model, selling directly to enterprise buyers via email, phone, and the company website. Revenue is earned through project-based contracts covering process development, scale-up, and ton-batch production of intermediates, with quote-based pricing that is not publicly disclosed. Primary customers are global pharmaceutical companies requiring intermediates manufactured under strict quality guidelines, plus specialty chemical buyers. In February 2024, the company materially expanded its customer base into U.S. defense/national security via an $86.2 million Department of Defense contract under the Defense Production Act Investments Program, with Lacamas required to co-invest 5% of construction costs to establish domestic manufacturing of critical energetics precursors, non-energetics precursors, and stabilizers/burning rate moderators historically sourced from overseas suppliers. The company is supported by an experienced leadership team including founder Allen Erickson (President/CEO) and Mack Young (VP Manufacturing, internally promoted since 2000), and a six-member board, with no external institutional equity investors disclosed.

Distribution leverages Portland's rail, air, and seaport infrastructure for international shipping of hazardous goods to Asia and Europe. The product portfolio includes catalog offerings such as DIBOC (di-tert-butyl dicarbonate), diisopropylzinc solution in xylene, isopropylmagnesium chloride solution, ethylmagnesium bromide solution, and diethyl p-toluenesulfonyloxymethylphosphonate, alongside custom synthesis services. Revenue figures, customer counts, and ownership structure beyond founder control are not publicly disclosed, though the DOD contract materially expands the company's addressable market and capital base.

Name

Lacamas Laboratories

Legal name

Lacamas Laboratories Inc.

Website

https://lacamaslabs.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

11–50 employees

Short description

Lacamas Laboratories is a privately-held custom manufacturer of pharmaceutical intermediates and fine chemicals headquartered in Portland, Oregon, with over 32,000 gallons of reactor capacity serving global pharmaceutical, specialty chemical, and U.S. Department of Defense customers.

Ownership category

akta.pro rank

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Infrastructure, Supply Chain, Technology or R&D

Revenue model

1. Custom synthesis and contract manufacturing: Lacamas Laboratories generates revenue through custom manufacturing of pharmaceutical intermediates and fine chemicals for global customers. The company develops and scales chemical processes on behalf of clients, producing compounds ranging from kilograms to tons. Revenue is earned through project-based contracts, including DOD defense contracts and commercial pharmaceutical engagements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Lacamas Laboratories is a custom manufacturer of high-quality pharmaceutical intermediates and fine chemicals, offering over 32,000 gallons of reactor capability across facilities in Portland and Albany, Oregon. The company provides process development, scale-up, and contract manufacturing from kilograms to tons, with expertise in hazardous, cryogenic, high-temperature, corrosive, and organometallic chemistries. It serves global pharmaceutical companies and the U.S. Department of Defense under cGMP and ISO 9001:2015 certified quality systems.

Product overview

Lacamas Laboratories is a custom manufacturer of high-quality pharmaceutical intermediates and fine chemicals, offering over 32,000 gallons of reactor capability. The company provides contract manufacturing services and a portfolio of specialty chemical products including Di-tert-butyl dicarbonate (DIBOC), diisopropylzinc solution, isopropylmagnesium chloride solution, ethylmagnesium bromide solution, and diethyl p-toluenesulfonyloxymethylphosphonate. Their capabilities include process development, scale-up, high-temperature and cryogenic chemistry, corrosive chemistries, continuous processing, and hazardous materials handling. They operate under cGMP compliance with ISO 9001:2015 certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Di-tert-butyl dicarbonate (DIBOC)

Quantifiable outcome

• Over 32,000 gallons of reactor capacity from 5 gallons to 2,000 gallons
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hovione: Privately-held pharmaceutical CDMO specializing in custom synthesis of active pharmaceutical ingredients and intermediates, including complex chemistries (cryogenic, organometallic, hazardous). Highly comparable to Lacamas in customer base (global pharma) and service offering (contract manufacturing at kg-to-ton scale).
• Cambrex: CDMO providing custom synthesis of pharmaceutical intermediates and APIs with expertise in complex chemistry including cryogenic and hazardous reactions. Direct competitor for Lacamas's pharmaceutical intermediate manufacturing business across multiple scales.
• Siegfried Holding: Swiss pharmaceutical CDMO offering custom manufacturing of APIs and intermediates from kg to ton scale. Direct competitor in pharmaceutical intermediate manufacturing with similar focus on complex chemistry and regulatory compliance (cGMP).
• Bachem: Leading CDMO specializing in peptide and oligonucleotide API manufacturing with custom synthesis capabilities. Comparable in pharmaceutical intermediate custom manufacturing and serving similar global pharmaceutical customers with stringent quality requirements.
• PCI Synthesis: U.S.-based pharmaceutical CDMO providing custom synthesis of APIs and intermediates, with capabilities in complex chemistry similar to Lacamas. Direct peer serving pharmaceutical customers requiring kg-to-ton scale custom manufacturing with cGMP compliance.
• Carbogen Amcis: Pharmaceutical CDMO specializing in API development and manufacturing with expertise in complex chemistry, highly potent APIs, and custom synthesis. Direct comparable to Lacamas in custom pharmaceutical intermediate manufacturing with similar regulatory and quality profile.

Broad incumbents

• Albemarle Corporation: Large specialty chemicals manufacturer serving pharmaceutical, defense, and industrial markets. Comparable in fine chemicals production capabilities and defense chemical exposure, though operating at significantly larger scale across broader product portfolio.
• Lonza Group: Global leader in pharmaceutical CDMO services with broad custom synthesis capabilities across small molecules, biologics, and cell therapies. While at much larger scale, Lonza competes directly for pharmaceutical intermediate custom manufacturing contracts that Lacamas targets.
• Thermo Fisher Scientific (Patheon): Global pharmaceutical services giant offering CDMO services through its Patheon business, including custom synthesis of pharmaceutical intermediates and APIs. Competes with Lacamas for commercial pharma custom manufacturing work at significantly larger scale.

Regional players

• EaglePicher Technologies: U.S. defense and aerospace manufacturer with capabilities in energetics and specialty chemicals for defense applications. Comparable to Lacamas in the DOD contract context for critical defense chemical manufacturing, particularly energetics-related materials.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lacamas-laboratories

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lacamas Laboratories